Cell-penetrating Peptide-mediated Nanovaccine Delivery

Jizong       Jiang
doi:10.2174/1389450122666210203193225
Abstract

Vaccination with small antigens, such as proteins, peptides, or nucleic acids, is used to activate the immune system and trigger the protective immune responses against a pathogen. Currently, nanovaccines are undergoing development instead of conventional vaccines. The size of nanovaccines is in the range of 10-500 nm, which enables them to be readily taken up by cells and exhibit improved safety profiles. However, low-level immune responses, as the removal of redundant pathogens, trigger counter-effective activation of the immune system invalidly and present a challenging obstacle to antigen recognition and its uptake via antigen-presenting cells (APCs). In addition, toxicity can be substantial. To overcome these problems, a variety of cell-penetrating peptide (CPP)-mediated vaccine delivery systems based on nanotechnology have been proposed, most of which are designed to improve the stability of antigens in vivo and their delivery into immune cells. CPPs are particularly attractive components of antigen delivery. Thus, the unique translocation property of CPPs ensures that they remain an attractive carrier with the capacity to deliver cargo in an efficient manner for the application of drugs, gene transfer, protein, and DNA/RNA vaccination delivery. CPP-mediated nanovaccines can enhance antigen uptake, processing, and presentation by APCs, which are the fundamental steps in initiating an immune response. This review describes the different types of CPP-based nanovaccines delivery strategies.
Keywords: Cell-penetrating peptide, nanoparticle, vaccine, immune response, delivery system, nanotechnology.
« Previous Next »
Graphical Abstract

[1] 
Alonso PL, Tanner M. Public health challenges and prospects for malaria control and elimination. Nat Med  2013; 19(2): 150-5.
[http://dx.doi.org/10.1038/nm.3077] [PMID: 23389615] 
[2] 
Alm JS, Lilja G, Pershagen G, Scheynius A. Early BCG vaccination and development of atopy. Lancet  1997; 350(9075): 400-3.
[http://dx.doi.org/10.1016/S0140-6736(97)02207-1] [PMID: 9259654] 
[3] 
Bull JJ. Evolutionary reversion of live viral vaccines: Can genetic engineering subdue it? Virus Evol  2015; 1(1): vev005.
[http://dx.doi.org/10.1093/ve/vev005] [PMID: 27034780] 
[4] 
Baxter D. Active and passive immunity, vaccine types, excipients and licensing. Occup Med (Lond)  2007; 57(8): 552-6.
[http://dx.doi.org/10.1093/occmed/kqm110] [PMID: 18045976] 
[5] 
Singh M, O’Hagan D. Advances in vaccine adjuvants. Nat Biotechnol  1999; 17(11): 1075-81.
[http://dx.doi.org/10.1038/15058] [PMID: 10545912] 
[6] 
Glenny AT, Pope CG, Waddington H, et al. Immunological notes. XVII–XXIV. J Pathol Bacteriol  1926; 29: 31-40.
[http://dx.doi.org/10.1002/path.1700290106] 
[7] 
Opie EL, Freund J. An experimental study of protective inoculation with heat killed tubercle bacilli. J Exp Med  1937; 66(6): 761-88.
[http://dx.doi.org/10.1084/jem.66.6.761] [PMID: 19870697] 
[8] 
Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell  1988; 55(6): 1189-93.
[http://dx.doi.org/10.1016/0092-8674(88)90263-2] [PMID: 2849510] 
[9] 
Green M, Loewenstein PM. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell  1988; 55(6): 1179-88.
[http://dx.doi.org/10.1016/0092-8674(88)90262-0] [PMID: 2849509] 
[10] 
Derossi D, Joliot AH, Chassaing G, Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem  1994; 269(14): 10444-50.
[PMID: 8144628] 
[11] 
Vasconcelos L, Pärn K, Langel U. Therapeutic potential of cell-penetrating peptides. Ther Deliv  2013; 4(5): 573-91.
[http://dx.doi.org/10.4155/tde.13.22] [PMID: 23647276] 
[12] 
Martin ME, Rice KG. Peptide-guided gene delivery. AAPS J  2007; 9(1): E18-29.
[http://dx.doi.org/10.1208/aapsj0901003] [PMID: 17408236] 
[13] 
Sawant R, Torchilin V. Intracellular transduction using cell-penetrating peptides. Mol Biosyst  2010; 6(4): 628-40.
[http://dx.doi.org/10.1039/B916297F] [PMID: 20237640] 
[14] 
Qian Z, Dougherty PG, Pei D. Monitoring the cytosolic entry of cell-penetrating peptides using a pH-sensitive fluorophore. Chem Commun (Camb)  2015; 51(11): 2162-5.
[http://dx.doi.org/10.1039/C4CC09441G] [PMID: 25554998] 
[15] 
Lindgren M, Rosenthal-Aizman K, Saar K, et al. Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide. Biochem Pharmacol  2006; 71(4): 416-25.
[http://dx.doi.org/10.1016/j.bcp.2005.10.048] [PMID: 16376307] 
[16] 
Margus H, Padari K, Pooga M. Cell-penetrating peptides as versatile vehicles for oligonucleotide delivery. Mol Ther  2012; 20(3): 525-33.
[http://dx.doi.org/10.1038/mt.2011.284] [PMID: 22233581] 
[17] 
Morris MC, Depollier J, Mery J, Heitz F, Divita G. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol  2001; 19(12): 1173-6.
[http://dx.doi.org/10.1038/nbt1201-1173] [PMID: 11731788] 
[18] 
Deshayes S, Morris MC, Divita G, Heitz F. Cell-penetrating peptides: tools for intracellular delivery of therapeutics. Cell Mol Life Sci  2005; 62(16): 1839-49.
[http://dx.doi.org/10.1007/s00018-005-5109-0] [PMID: 15968462] 
[19] 
Galdiero S, Falanga A, Vitiello M, et al. Exploitation of viral properties for intracellular delivery. J Pept Sci  2014; 20(7): 468-78.
[http://dx.doi.org/10.1002/psc.2649] [PMID: 24889153] 
[20] 
Skwarczynski M, Toth I. Cell-penetrating peptides in vaccine delivery: facts, challenges and perspectives. Ther Deliv  2019; 10(8): 465-7.
[http://dx.doi.org/10.4155/tde-2019-0042] [PMID: 31462173] 
[21] 
Liu F, Shollenberger LM, Conwell CC, Yuan X, Huang L. Mechanism of naked DNA clearance after intravenous injection. J Gene Med  2007; 9(7): 613-9.
[http://dx.doi.org/10.1002/jgm.1054] [PMID: 17534886] 
[22] 
Lai E, van Zanten JH. Evidence of lipoplex dissociation in liquid formulations. J Pharm Sci  2002; 91(5): 1225-32.
[http://dx.doi.org/10.1002/jps.10108] [PMID: 11977098] 
[23] 
Lv H, Zhang S, Wang B, Cui S, Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release  2006; 114(1): 100-9.
[http://dx.doi.org/10.1016/j.jconrel.2006.04.014] [PMID: 16831482] 
[24] 
Bolhassani A, Safaiyan S, Rafati S. Improvement of different vaccine delivery systems for cancer therapy. Mol Cancer  2011; 10: 3.
[http://dx.doi.org/10.1186/1476-4598-10-3] [PMID: 21211062] 
[25] 
Liu Y, Chen C. Role of nanotechnology in HIV/AIDS vaccine development. Adv Drug Deliv Rev  2016; 103: 76-89.
[http://dx.doi.org/10.1016/j.addr.2016.02.010] [PMID: 26952542] 
[26] 
Ahmed TA, Aljaeid BM. Preparation, characterization, and potential application of chitosan, chitosan derivatives, and chitosan metal nanoparticles in pharmaceutical drug delivery. Drug Des Devel Ther  2016; 10: 483-507.
[http://dx.doi.org/10.2147/DDDT.S99651] [PMID: 26869768] 
[27] 
Sun B, Xia T. Nanomaterial-based vaccine adjuvants. J Mater Chem B Mater Biol Med  2016; 4(33): 5496-509.
[http://dx.doi.org/10.1039/C6TB01131D] [PMID: 30774955] 
[28] 
Hu Y, Hoerle R, Ehrich M, Zhang C. Engineering the lipid layer of lipid-PLGA hybrid nanoparticles for enhanced in vitro cellular uptake and improved stability. Acta Biomater  2015; 28: 149-59.
[http://dx.doi.org/10.1016/j.actbio.2015.09.032] [PMID: 26428192] 
[29] 
Wang X, Yang D, Li S, Xu X, Qin CF, Tang R. Biomineralized vaccine nanohybrid for needle-free intranasal immunization. Biomaterials  2016; 106: 286-94.
[http://dx.doi.org/10.1016/j.biomaterials.2016.08.035] [PMID: 27575530] 
[30] 
Klippstein R, Pozo D. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. Nanomedicine (Lond)  2010; 6(4): 523-9.
[http://dx.doi.org/10.1016/j.nano.2010.01.001] [PMID: 20085824] 
[31] 
Kale AA, Torchilin VP. Enhanced transfection of tumor cells in vivo using “Smart” pH-sensitive TAT-modified pegylated liposomes. J Drug Target  2007; 15(7-8): 538-45.
[http://dx.doi.org/10.1080/10611860701498203] [PMID: 17671900] 
[32] 
Maiolo JR, Ferrer M, Ottinger EA. Effects of cargo molecules on the cellular uptake of arginine-rich cell-penetrating peptides. Biochim Biophys Acta  2005; 1712(2): 161-72.
[http://dx.doi.org/10.1016/j.bbamem.2005.04.010] [PMID: 15935328] 
[33] 
Derossi D, Calvet S, Trembleau A, Brunissen A, Chassaing G, Prochiantz A. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J Biol Chem  1996; 271(30): 18188-93.
[http://dx.doi.org/10.1074/jbc.271.30.18188] [PMID: 8663410] 
[34] 
Sokolov Y, Mirzabekov T, Martin DW, Lehrer RI, Kagan BL. Membrane channel formation by antimicrobial protegrins. Biochim Biophys Acta  1999; 1420(1-2): 23-9.
[http://dx.doi.org/10.1016/S0005-2736(99)00086-3] [PMID: 10446287] 
[35] 
Koren E, Apte A, Sawant RR, Grunwald J, Torchilin VP. Cell-penetrating TAT peptide in drug delivery systems: proteolytic stability requirements. Drug Deliv  2011; 18(5): 377-84.
[http://dx.doi.org/10.3109/10717544.2011.567310] [PMID: 21438724] 
[36] 
Marasini N, Giddam AK, Batzloff MR, et al. Poly-L-lysine-coated nanoparticles are ineffective in inducing mucosal immunity against group a streptococcus. Bio Chem Comp  2017; 5: 1-6.
[http://dx.doi.org/10.7243/2052-9341-5-1] 
[37] 
Tang J, Yin R, Tian Y, et al. A novel self-assembled nanoparticle vaccine with HIV-1 Tat (49-57)/HPV16 E7(49-57) fusion peptide and GM-CSF DNA elicits potent and prolonged CD8(+) T cell-dependent anti-tumor immunity in mice. Vaccine  2012; 30(6): 1071-82.
[http://dx.doi.org/10.1016/j.vaccine.2011.12.029] [PMID: 22178528] 
[38] 
Mohri K, Miyata K, Egawa T, et al. Effects of the chemical structures of oligoarginines conjugated to biocompatible polymers as a mucosal adjuvant on antibody induction in nasal cavities. Chem Pharm Bull (Tokyo)  2018; 66(4): 375-81.
[http://dx.doi.org/10.1248/cpb.c17-00834] [PMID: 29607903] 
[39] 
Schutze-Redelmeier MPM, Kong S, Bally MB, Dutz JP. Antennapedia transduction sequence promotes anti tumour immunity to epicutaneously administered CTL epitopes. Vaccine  2004; 22(15-16): 1985-91.
[http://dx.doi.org/10.1016/j.vaccine.2003.10.028] [PMID: 15121311] 
[40] 
Deshayes S, Plénat T, Aldrian-Herrada G, Divita G, Le Grimellec C, Heitz F. Primary amphipathic cell-penetrating peptides: structural requirements and interactions with model membranes. Biochemistry  2004; 43(24): 7698-706.
[http://dx.doi.org/10.1021/bi049298m] [PMID: 15196012] 
[41] 
Yu X, Wang Y, Xia Y, Zhang L, Yang Q, Lei J. A DNA vaccine encoding VP22 of herpes simplex virus type I (HSV-1) and OprF confers enhanced protection from Pseudomonas aeruginosa in mice. Vaccine  2016; 34(37): 4399-405.
[http://dx.doi.org/10.1016/j.vaccine.2016.07.017] [PMID: 27449680] 
[42] 
Mardani G, Bolhassani A, Agi E, Shahbazi S, Mehdi Sadat S. Protein vaccination with HPV16 E7/Pep-1 nanoparticles elicits a protective T-helper cell-mediated immune response. IUBMB Life  2016; 68(6): 459-67.
[http://dx.doi.org/10.1002/iub.1503] [PMID: 27094221] 
[43] 
Pujals S, Giralt E. Proline-rich, amphipathic cell-penetrating peptides. Adv Drug Deliv Rev  2008; 60(4-5): 473-84.
[http://dx.doi.org/10.1016/j.addr.2007.09.012] [PMID: 18187229] 
[44] 
Kardani K, Milani A, H Shabani S, Bolhassani A. Cell penetrating peptides: the potent multi-cargo intracellular carriers. Expert Opin Drug Deliv  2019; 16(11): 1227-58.
[http://dx.doi.org/10.1080/17425247.2019.1676720] [PMID: 31583914] 
[45] 
Veach RA, Liu D, Yao S, et al. Receptor/transporter-independent targeting of functional peptides across the plasma membrane. J Biol Chem  2004; 279(12): 11425-31.
[http://dx.doi.org/10.1074/jbc.M311089200] [PMID: 14699109] 
[46] 
Mayor S, Parton RG, Donaldson JG. Clathrin-independent pathways of endocytosis. Cold Spring Harb Perspect Biol  2014; 6(6): 1-20.
[http://dx.doi.org/10.1101/cshperspect.a016758] [PMID: 24890511] 
[47] 
Yang J, Luo Y, Shibu MA, Toth I, Skwarczynskia M. Cell-penetrating peptides: efficient vectors for vaccine delivery. Curr Drug Deliv  2019; 16(5): 430-43.
[http://dx.doi.org/10.2174/1567201816666190123120915] [PMID: 30760185] 
[48] 
Mai JC, Shen H, Watkins SC, Cheng T, Robbins PD. Efficiency of protein transduction is cell type-dependent and is enhanced by dextran sulfate. J Biol Chem  2002; 277(33): 30208-18.
[http://dx.doi.org/10.1074/jbc.M204202200] [PMID: 12034749] 
[49] 
Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages. Annu Rev Immunol  1999; 17: 593-623.
[http://dx.doi.org/10.1146/annurev.immunol.17.1.593] [PMID: 10358769] 
[50] 
Hillaireau H, Couvreur P. Nanocarriers’ entry into the cell: relevance to drug delivery. Cell Mol Life Sci  2009; 66(17): 2873-96.
[http://dx.doi.org/10.1007/s00018-009-0053-z] [PMID: 19499185] 
[51] 
Maniti O, Piao HR, Ayala-Sanmartin J. Basic cell penetrating peptides induce plasma membrane positive curvature, lipid domain separation and protein redistribution. Int J Biochem Cell Biol  2014; 50: 73-81.
[http://dx.doi.org/10.1016/j.biocel.2014.02.017] [PMID: 24583633] 
[52] 
Tali C. Scavenger receptors as a target for nucleic acid delivery with peptide vectors. University of Tarita Press 2017.
[53] 
Ván ová J, Hejtmánková AT, Kalbác ová MH. The utilization of cell-penetrating peptides in the intracellular delivery of viral nanoparticles. Materials  2019; 12: 2671.
[54] 
Winkler J. Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides. Ther Deliv  2011; 2(7): 891-905.
[http://dx.doi.org/10.4155/tde.11.56] [PMID: 22318893] 
[55] 
Kim H, Seo EH, Lee SH, Kim BJ. The telomerase-derived anticancer peptide vaccine GV1001 as an extracellular heat shock protein-mediated cell-penetrating peptide. Int J Mol Sci  2016; 17(12): 2054.
[http://dx.doi.org/10.3390/ijms17122054] [PMID: 27941629] 
[56] 
Lee SA, Kim BR, Kim BK, et al. Heat shock protein-mediated cell penetration and cytosolic delivery of macromolecules by a telomerase-derived peptide vaccine. Biomaterials  2013; 34(30): 7495-505.
[http://dx.doi.org/10.1016/j.biomaterials.2013.06.015] [PMID: 23827187] 
[57] 
Wang RF, Wang HY. Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells. Nat Biotechnol  2002; 20(2): 149-54.
[http://dx.doi.org/10.1038/nbt0202-149] [PMID: 11821860] 
[58] 
Seesuay W, Jittavisutthikul S, Sae-Lim N, Sookrung N, Sakolvaree Y, Chaicumpa W. Human transbodies that interfere with the functions of Ebola virus VP35 protein in genome replication and transcription and innate immune antagonism. Emerg Microbes Infect  2018; 7(1): 41.
[http://dx.doi.org/10.1038/s41426-018-0031-3] [PMID: 29568066] 
[59] 
Lim S, Koo JH, Choi JM. Use of cell-penetrating peptides in dendritic cell-based vaccination. Immune Netw  2016; 16(1): 33-43.
[http://dx.doi.org/10.4110/in.2016.16.1.33] [PMID: 26937230] 
[60] 
Al-Husaini K, Elkamel E, Han XX, et al. Therapeutic potential of a cell penetrating peptide (CPP, NP1) mediated siRNA delivery: Evidence in 3D spheroids of colon cancer cells. Can J Chem Eng  2020; 98: 1240-54.
[http://dx.doi.org/10.1002/cjce.23743] 
[61] 
Davoodi S, Bolhassani A, Sadat SM, Irani S. Design and in vitro delivery of HIV-1 multi-epitope DNA and peptide constructs using novel cell-penetrating peptides. Biotechnol Lett  2019; 41(11): 1283-98.
[http://dx.doi.org/10.1007/s10529-019-02734-x] [PMID: 31531750] 
[62] 
Muto K, Kamei N, Yoshida M, Takayama K, Takeda-Morishita M. Cell-penetrating peptide penetratin as a potential tool for developing effective nasal vaccination systems. J Pharm Sci  2016; 105(6): 2014-7.
[http://dx.doi.org/10.1016/j.xphs.2016.03.026] [PMID: 27155764] 
[63] 
Alizadeh S, Irani S, Bolhassani A, Sadat SM. Simultaneous use of natural adjuvants and cell penetrating peptides improves HCV NS3 antigen-specific immune responses. Immunol Lett  2019; 212: 70-80.
[http://dx.doi.org/10.1016/j.imlet.2019.06.011] [PMID: 31254535] 
[64] 
Shahbazi S, Bolhassani A. Comparison of six cell penetrating peptides with different properties for in vitro and in vivo delivery of HPV16 E7 antigen in therapeutic vaccines. Int Immunopharmacol  2018; 62: 170-80.
[http://dx.doi.org/10.1016/j.intimp.2018.07.006] [PMID: 30015237] 
[65] 
Lam P, Steinmetz NF. Delivery of siRNA therapeutics using cowpea chlorotic mottle virus-like particles. Biomater Sci  2019; 7(8): 3138-42.
[http://dx.doi.org/10.1039/C9BM00785G] [PMID: 31257379] 
[66] 
Zhang TT, Kang TH, Ma B, Xu Y, Hung CF, Wu TC. LAH4 enhances CD8+ T cell immunity of protein/peptide-based vaccines. Vaccine  2012; 30(4): 784-93.
[http://dx.doi.org/10.1016/j.vaccine.2011.11.056] [PMID: 22120194] 
[67] 
Shi XG, Song HJ, Wang CG, et al. Co-assembled and self-delivered epitope/CpG nanocomplex vaccine T augments peptide immunogenicity for cancer immunotherapy. Chem Eng J  2020; 399: 125854.
[http://dx.doi.org/10.1016/j.cej.2020.125854] 
[68] 
Mehrlatifan S, Mirnurollahi SM, Motevalli F, Rahimi P, Soleymani S, Bolhassani A. The structural HCV genes delivered by MPG cell penetrating peptide are directed to enhance immune responses in mice model. Drug Deliv  2016; 23(8): 2852-9.
[http://dx.doi.org/10.3109/10717544.2015.1108375] [PMID: 26559939] 
[69] 
Fang WB, Yao M, Brummer G, et al. Targeted gene silencing of CCL2 inhibits triple negative breast cancer progression by blocking cancer stem cell renewal and M2 macrophage recruitment. Oncotarget  2016; 7(31): 49349-67.
[http://dx.doi.org/10.18632/oncotarget.9885] [PMID: 27283985] 
[70] 
Sun Y, Hu YH. Cell-penetrating peptide-mediated subunit vaccine generates a potent immune response and protection against Streptococcus iniae in Japanese flounder (Paralichthys olivaceus). Vet Immunol Immunopathol  2015; 167(3-4): 96-103.
[http://dx.doi.org/10.1016/j.vetimm.2015.07.008] [PMID: 26232860] 
[71] 
Ma J, Xu J, Guan L, et al. Cell-penetrating peptides mediated protein cross-membrane delivery and its use in bacterial vector vaccine. Fish Shellfish Immunol  2014; 39(1): 8-16.
[http://dx.doi.org/10.1016/j.fsi.2014.04.003] [PMID: 24746937] 
[72] 
Granadillo M, Vallespi MG, Batte A, et al. A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice. Vaccine  2011; 29(5): 920-30.
[http://dx.doi.org/10.1016/j.vaccine.2010.11.083] [PMID: 21145912] 
[73] 
Yanez RJR, Lamprecht R, Granadillo M, et al. Expression optimization of a cell membrane-penetrating human papillomavirus type 16 therapeutic vaccine candidate in Nicotiana benthamiana. PLoS One  2017; 12(8): e0183177.
[http://dx.doi.org/10.1371/journal.pone.0183177] [PMID: 28800364] 
[74] 
Alfonso AB, Granadillo M, Batte A, et al. Biological activity of LALF32-51–E7, a vaccine candidate for the treatment of anogenital lesions associated to HPV16. J Cell Immun  2018; 4: 71-4.
[http://dx.doi.org/10.1016/j.jocit.2018.07.001] 
[75] 
Derouazi M, Di Berardino-Besson W, Belnoue E, et al. Novel cell-penetrating peptide-based vaccine induces robust CD4 and CD8 T cell–mediated antitumor immunity. Cancer Res  2015; 75(15): 3020-31.
[http://dx.doi.org/10.1158/0008-5472.CAN-14-3017] [PMID: 26116496] 
[76] 
Jagot-Lacoussiere L, Kotula E, Villoutreix BO, Bruzzoni-Giovanelli H, Poyet JL. A cell-penetrating peptide targeting AAC-11 specifically induces cancer cells death. Cancer Res  2016; 76(18): 5479-90.
[http://dx.doi.org/10.1158/0008-5472.CAN-16-0302] [PMID: 27406828] 
[77] 
Endoh T, Sisido M, Ohtsuki T. Cellular siRNA delivery mediated by a cell-permeant RNA-binding protein and photoinduced RNA interference. Bioconjug Chem  2008; 19(5): 1017-24.
[http://dx.doi.org/10.1021/bc800020n] [PMID: 18442282] 
[78] 
Bleifuss E, Kammertoens T, Hutloff A, et al. The translocation motif of hepatitis B virus improves protein vaccination. Cell Mol Life Sci  2006; 63(5): 627-35.
[http://dx.doi.org/10.1007/s00018-005-5548-7] [PMID: 16482397] 
[79] 
Rostami B, Irani S, Bolhassani A, Cohan RA. Gene and protein delivery using four cell penetrating peptides for HIV-1 vaccine development. IUBMB Life  2019; 71(10): 1619-33.
[http://dx.doi.org/10.1002/iub.2107] [PMID: 31220406] 
[80] 
Saleh T, Bolhassani A, Shojaosadati SA, Aghasadeghi MR. MPG-based nanoparticle: An efficient delivery system for enhancing the potency of DNA vaccine expressing HPV16E7. Vaccine  2015; 33(28): 3164-70.
[http://dx.doi.org/10.1016/j.vaccine.2015.05.015] [PMID: 26001433] 
[81] 
Fuenmayor J, Gòdia F, Cervera L. Production of virus-like particles for vaccines. N Biotechnol  2017; 39(Pt B): 174-80.
[http://dx.doi.org/10.1016/j.nbt.2017.07.010] [PMID: 28778817] 
[82] 
Riley MK, Vermerris W. Recent advances in nanomaterials for gene delivery—a review. Nanomaterials (Basel)  2017; 7(5): 94.
[http://dx.doi.org/10.3390/nano7050094] [PMID: 28452950] 
[83] 
Bolhassani A, Jafarzade BS, Mardani G. In vitro and in vivo delivery of therapeutic proteins using cell penetrating peptides. Peptides  2017; 87: 50-63.
[http://dx.doi.org/10.1016/j.peptides.2016.11.011] [PMID: 27887988] 
[84] 
Takenobu T, Tomizawa K, Matsushita M, et al. Development of p53 protein transduction therapy using membrane-permeable peptides and the application to oral cancer cells. Mol Cancer Ther  2002; 1(12): 1043-9.
[PMID: 12481427] 
[85] 
Sun Y, Sun Y, Zhao R, Gao K. Intracellular delivery of messenger RNA by recombinant PP7 virus-like particles carrying low molecular weight protamine. BMC Biotechnol  2016; 16(1): 46.
[http://dx.doi.org/10.1186/s12896-016-0274-9] [PMID: 27233770] 
[86] 
Pan Y, Zhang Y, Jia T, Zhang K, Li J, Wang L. Development of a microRNA delivery system based on bacteriophage MS2 virus-like particles. FEBS J  2012; 279(7): 1198-208.
[http://dx.doi.org/10.1111/j.1742-4658.2012.08512.x] [PMID: 22309233] 
[87] 
Lee HB, Yoon SY, Singh B, et al. Oral immunization of FMDV vaccine using pH-sensitive and mucoadhesive thiolated cellulose acetate phthalate microparticles. Tissue Eng Regen Med  2017; 15(1): 1-11.
[http://dx.doi.org/10.1007/s13770-017-0082-x] [PMID: 30603530] 
[88] 
Petrovsky N. Comparative safety of vaccine adjuvants: A summary of current evidence and future Needs. Drug Saf  2015; 38(11): 1059-74.
[http://dx.doi.org/10.1007/s40264-015-0350-4] [PMID: 26446142] 
[89] 
Erazo-Oliveras A, Muthukrishnan N, Baker R, Wang TY, Pellois JP. Improving the endosomal escape of cell-penetrating peptides and their cargos: strategies and challenges. Pharmaceuticals (Basel)  2012; 5(11): 1177-209.
[http://dx.doi.org/10.3390/ph5111177] [PMID: 24223492] 
[90] 
Richard JP, Melikov K, Vives E, et al. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem  2003; 278(1): 585-90.
[http://dx.doi.org/10.1074/jbc.M209548200] [PMID: 12411431] 
[91] 
Vijayan V, Mohapatra A, Uthaman S, et al. Improving the endosomal escape of cell-penetrating peptides and their cargos: strategies and challenges. Pharmaceutics  2019; 11: 534.
[http://dx.doi.org/10.3390/pharmaceutics11100534] 
[92] 
Wang J, Hu X, Xiang D. Nanoparticle drug delivery systems: an excellent carrier for tumor peptide vaccines. Drug Deliv  2018; 25(1): 1319-27.
[http://dx.doi.org/10.1080/10717544.2018.1477857] [PMID: 29869539] 
[93] 
Müller LK, Landfester K. Natural liposomes and synthetic polymeric structures for biomedical applications. Biochem Biophys Res Commun  2015; 468(3): 411-8.
[http://dx.doi.org/10.1016/j.bbrc.2015.08.088] [PMID: 26315266] 
[94] 
Schroeder A, Levins CG, Cortez C, Langer R, Anderson DG. Lipid-based nanotherapeutics for siRNA delivery. J Intern Med  2010; 267(1): 9-21.
[http://dx.doi.org/10.1111/j.1365-2796.2009.02189.x] [PMID: 20059641] 
[95] 
Tseng YL, Liu JJ, Hong RL. Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: a kinetic and efficacy study. Mol Pharmacol  2002; 62(4): 864-72.
[http://dx.doi.org/10.1124/mol.62.4.864] [PMID: 12237333] 
[96] 
Fretz MM, Koning GA, Mastrobattista E, Jiskoot W, Storm G. OVCAR-3 cells internalize TAT-peptide modified liposomes by endocytosis. Biochim Biophys Acta  2004; 1665(1-2): 48-56.
[http://dx.doi.org/10.1016/j.bbamem.2004.06.022] [PMID: 15471570] 
[97] 
Torchilin VP. Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery. Biopolymers  2008; 90(5): 604-10.
[http://dx.doi.org/10.1002/bip.20989] [PMID: 18381624] 
[98] 
Pappalardo JS, Quattrocchi V, Langellotti C, et al. Improved transfection of spleen-derived antigen-presenting cells in culture using TATp-liposomes. J Control Release  2009; 134(1): 41-6.
[http://dx.doi.org/10.1016/j.jconrel.2008.11.006] [PMID: 19059290] 
[99] 
Liu J, Zhang Q, Remsen EE, Wooley KL. Nanostructured materials designed for cell binding and transduction. Biomacromolecules  2001; 2(2): 362-8.
[http://dx.doi.org/10.1021/bm015515c] [PMID: 11749193] 
[100] 
Torchilin VP, Rammohan R, Weissig V, Levchenko TS. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc Natl Acad Sci USA  2001; 98(15): 8786-91.
[http://dx.doi.org/10.1073/pnas.151247498] [PMID: 11438707] 
[101] 
Mattern-Schain SI, Fisher RK, West PC, et al. Cell mimetic liposomal nanocarriers for tailored delivery of vascular therapeutics. Chem Phys Lipids  2019; 218: 149-57.
[http://dx.doi.org/10.1016/j.chemphyslip.2018.12.009] [PMID: 30582896] 
[102] 
Nakamura T, Moriguchi R, Kogure K, Shastri N, Harashima H. Efficient MHC class I presentation by controlled intracellular trafficking of antigens in octaarginine-modified liposomes. Mol Ther  2008; 16(8): 1507-14.
[http://dx.doi.org/10.1038/mt.2008.122] [PMID: 18560420] 
[103] 
Nakamura T, Ono K, Suzuki Y, Moriguchi R, Kogure K, Harashima H. Octaarginine-modified liposomes enhance cross-presentation by promoting the C-terminal trimming of antigen peptide. Mol Pharm  2014; 11(8): 2787-95.
[http://dx.doi.org/10.1021/mp500147y] [PMID: 24901376] 
[104] 
Lim M, Badruddoza AZM, Firdous J, et al. Engineered nanodelivery systems to improve DNA vaccine technologies. Pharmaceutics  2020; 12(1): 1-29.
[http://dx.doi.org/10.3390/pharmaceutics12010030] [PMID: 31906277] 
[105] 
Hong SJ, Ahn MH, Lee YW, et al. Biodegradable polymeric nanocarrier-Based immunotherapy in hepatitis vaccination in cutting-edge enabling technologies for regenerative medicine.  Berlin, Germany: Springer 2018; pp. 303-20.
[http://dx.doi.org/10.1007/978-981-13-0950-2_16] 
[106] 
Shae D, Postma A, Wilson JT. Vaccine delivery: Where polymer chemistry meets immunology. Future Sci  2016; 7.
[107] 
Shen C, Li J, Zhang Y, et al. Polyethylenimine-based micro/nanoparticles as vaccine adjuvants. Int J Nanomedicine  2017; 12: 5443-60.
[http://dx.doi.org/10.2147/IJN.S137980] [PMID: 28814862] 
[108] 
Torchilin VP. Tatp-mediated intracellular delivery of pharmaceutical nanocarriers. Biochem Soc Trans  2007; 35(Pt 4): 816-20.
[http://dx.doi.org/10.1042/BST0350816] [PMID: 17635155] 
[109] 
Shahbazi R, Asik E, Kahraman N, Turk M, Ozpolat B, Ulubayram K. Modified gold-based siRNA nanotherapeutics for targeted therapy of triple-negative breast cancer. Nanomedicine (Lond)  2017; 12(16): 1961-73.
[http://dx.doi.org/10.2217/nnm-2017-0081] [PMID: 28745127] 
[110] 
Niu J, Chu Y, Huang YF, et al. Transdermal gene delivery by functional peptide-conjugated cationic gold nanoparticle reverses the progression and metastasis of cutaneous melanoma. ACS Appl Mater Interfaces  2017; 9(11): 9388-401.
[http://dx.doi.org/10.1021/acsami.6b16378] [PMID: 28252938] 
[111] 
Chereddy KK, Vandermeulen G, Préat V. PLGA based drug delivery systems: Promising carriers for wound healing activity. Wound Repair Regen  2016; 24(2): 223-36.
[http://dx.doi.org/10.1111/wrr.12404] [PMID: 26749322] 
[112] 
Liu SY, Wei W, Yue H, et al. Nanoparticles-based multi-adjuvant whole cell tumor vaccine for cancer immunotherapy. Biomaterials  2013; 34(33): 8291-300.
[http://dx.doi.org/10.1016/j.biomaterials.2013.07.020] [PMID: 23910466] 
[113] 
Liu X, Liu J, Liu D, et al. A cell-penetrating peptide-assisted nanovaccine promotes antigen cross-presentation and anti-tumor immune response. Biomater Sci  2019; 7(12): 5516-27.
[http://dx.doi.org/10.1039/C9BM01183H] [PMID: 31670734] 
[114] 
Coolen AL, Lacroix C, Mercier-Gouy P, et al. Poly(lactic acid) nanoparticles and cell-penetrating peptide potentiate mRNA-based vaccine expression in dendritic cells triggering their activation. Biomaterials  2019; 195: 23-37.
[http://dx.doi.org/10.1016/j.biomaterials.2018.12.019] [PMID: 30610991] 
[115] 
Zhang N, Chen H, Liu AY, et al. Gold conjugate-based liposomes with hybrid cluster bomb structure for liver cancer therapy. Biomaterials  2016; 74: 280-91.
[http://dx.doi.org/10.1016/j.biomaterials.2015.10.004] [PMID: 26461120] 
[116] 
Pack DW, Hoffman AS, Pun S, Stayton PS. Design and development of polymers for gene delivery. Nat Rev Drug Discov  2005; 4(7): 581-93.
[http://dx.doi.org/10.1038/nrd1775] [PMID: 16052241] 
[117] 
Malhotra M, Tomaro-Duchesneau C, Saha S, Prakash S. siRNA delivery to the brain by TAT/MGF tagged PEGylated chitosan nanoparticles. J Pharm (Cairo)  2013; 2013: 812387.
[http://dx.doi.org/10.1155/2013/812387] [PMID: 26555995] 
[118] 
Wang CQ, Wu JL, Zhuo RX, Cheng SX. Protamine sulfate-calcium carbonate-plasmid DNA ternary nanoparticles for efficient gene delivery. Mol Biosyst  2014; 10(3): 672-8.
[http://dx.doi.org/10.1039/c3mb70502a] [PMID: 24442276] 
[119] 
Wang K, Yang Y, Xue W, Liu Z. Cell Penetrating peptide-based redox-sensitive vaccine delivery system for subcutaneous vaccination. Mol Pharm  2018; 15(3): 975-84.
[http://dx.doi.org/10.1021/acs.molpharmaceut.7b00905] [PMID: 29359945] 
[120] 
Ryoo SR, Jang H, Kim KS, et al. Functional delivery of DNAzyme with iron oxide nanoparticles for hepatitis C virus gene knockdown. Biomaterials  2012; 33(9): 2754-61.
[http://dx.doi.org/10.1016/j.biomaterials.2011.12.015] [PMID: 22206595] 
[121] 
Wang ZY, Zhao Y, Ren L, et al. Novel gelatin-siloxane nanoparticles decorated by Tat peptide as vectors for gene therapy. Nanotechnology  2008; 19(44): 445103.
[http://dx.doi.org/10.1088/0957-4484/19/44/445103] [PMID: 21832720] 
[122] 
Shen Y, Qiu L. Effective oral delivery of gp100 plasmid vaccine against metastatic melanoma through multi-faceted blending-by-blending nanogels. Nanomedicine (Lond)  2019; 22: 102114.
[http://dx.doi.org/10.1016/j.nano.2019.102114] [PMID: 31655203] 
[123] 
Sakuma S, Suita M, Inoue S, et al. Cell-penetrating peptide-linked polymers as carriers for mucosal vaccine delivery. Mol Pharm  2012; 9(10): 2933-41.
[http://dx.doi.org/10.1021/mp300329r] [PMID: 22953762] 
[124] 
Gwak SJ, Nice J, Zhang J, et al. Cationic, amphiphilic copolymer micelles as nucleic acid carriers for enhanced transfection in rat spinal cord. Acta Biomater  2016; 35: 98-108.
[http://dx.doi.org/10.1016/j.actbio.2016.02.013] [PMID: 26873365] 
[125] 
Kanazawa T, Akiyama F, Kakizaki S, Takashima Y, Seta Y. Delivery of siRNA to the brain using a combination of nose-to-brain delivery and cell-penetrating peptide-modified nano-micelles. Biomaterials  2013; 34(36): 9220-6.
[http://dx.doi.org/10.1016/j.biomaterials.2013.08.036] [PMID: 23992922] 
[126] 
Kanazawa T, Kurano Y, Ibaraki H, et al. Therapeutic effects in a transient middle cerebral artery occlusion rat model by nose-to-brain delivery of anti-TNF-alpha siRNA with cell-penetrating peptide-modified polymer micelles. Pharmaceutics  2019; 11: 478.
[http://dx.doi.org/10.3390/pharmaceutics11090478] 
[127] 
Becker ML, Bailey LO, Wooley KL. Peptide-derivatized shell-cross-linked nanoparticles. 2. Biocompatibility evaluation. Bioconjug Chem  2004; 15(4): 710-7.
[http://dx.doi.org/10.1021/bc049945m] [PMID: 15264857] 
[128] 
Zope H, Quer CB, Bomans PH, Sommerdijk NA, Kros A, Jiskoot W. Peptide amphiphile nanoparticles enhance the immune response against a CpG-adjuvanted influenza antigen. Adv Healthc Mater  2014; 3(3): 343-8.
[http://dx.doi.org/10.1002/adhm.201300247] [PMID: 23983195] 
[129] 
Choi SW, Lee SH, Mok H, Park TG. Multifunctional siRNA delivery system: polyelectrolyte complex micelles of six-arm PEG conjugate of siRNA and cell penetrating peptide with crosslinked fusogenic peptide. Biotechnol Prog  2010; 26(1): 57-63.
[PMID: 19918765] 
[130] 
Rádis-Baptista G, Campelo IS, Morlighem JRL, Melo LM, Freitas VJF. Cell-penetrating peptides (CPPs): From delivery of nucleic acids and antigens to transduction of engineered nucleases for application in transgenesis. J Biotechnol  2017; 252: 15-26.
[http://dx.doi.org/10.1016/j.jbiotec.2017.05.002] [PMID: 28479163] 
[131] 
Olson ES, Aguilera TA, Jiang T, et al. In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integr Biol  2009; 1(5-6): 382-93.
[http://dx.doi.org/10.1039/b904890a] [PMID: 20023745] 
[132] 
Bolton SJ, Jones DNC, Darker JG, Eggleston DS, Hunter AJ, Walsh FS. Cellular uptake and spread of the cell-permeable peptide penetratin in adult rat brain. Eur J Neurosci  2000; 12(8): 2847-55.
[http://dx.doi.org/10.1046/j.1460-9568.2000.00171.x] [PMID: 10971627] 
[133] 
Low W, Mortlock A, Petrovska L, Dottorini T, Dougan G, Crisanti A. Functional cell permeable motifs within medically relevant proteins. J Biotechnol  2007; 129(3): 555-64.
[http://dx.doi.org/10.1016/j.jbiotec.2007.01.019] [PMID: 17331607] 
Rights & Permissions Print Cite
Article Metrics
43
1
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1389450122666210203193225	Print ISSN 1389-4501
Publisher Name Bentham Science Publisher	Online ISSN 1873-5592
Current Drug Targets

Cell-penetrating Peptide-mediated Nanovaccine Delivery

Abstract Play Pause

Graphical Abstract

Related Journals

Related Books

Related Articles

Abstract
